MAY 14, 2020 4:40 PM CEST

Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers

Speaker
  • Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital
    Biography
      Marianne Grantham is a Clinical Scientist and Head of the Cytogenetics and Molecular Haematology Department at Barts Health NHS Trust in London. After graduating from the University of Birmingham with a Bachelor's degree in Genetics in 1996, she joined the NHS to train as a Clinical Cytogeneticist. Early on in her career she discovered her passion lay in the genomics of haematological malignancies and its integration into clinical care. Marianne has worked in several large teaching hospitals across the globe including Great Ormond Street Hospital for Sick Children and St Vincent's Hospital in Sydney Australia and has worked at Barts Health since 2003. Marianne has a specialist interest in training and people development including making genomics accessible for all healthcare staff and is an honorary lecturer at Queen Mary, University of London. In 2019, Marianne was appointed as the Lead Scientist for Haematological Malignancies for the North Thames Genomic Laboratory Hub.

    Abstract

    Comprehensive genomic profiling of myeloid and, increasingly more, lymphoid malignancies is becoming an essential part of clinical diagnostics to improve diagnosis, assist therapeutic decisions, and provide better information about prognosis. Introduction of next-generation sequencing (NGS) into the for the profiling can be a solution for future. However it can bring challenges as well as benefits. Our institutions’ journey to introduce NGS into an integrated laboratory is discussed. The practical issues around panel content and data quality are also summarized.

     

    Learning Objectives:

    1. Understand the benefits of next-generation sequencing in the profiling  of haematological malignancies 

    2. Develop an awareness of the practicalities of introducing new technologies to a medical laboratory


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    Loading Comments...
    Show Resources